Objective 5 of the NZ Antimicrobial Resistance Action Plan is to establish and support clear governance, collaboration and investment arrangements for a sustainable approach to countering antimicrobial resistance.
Priority areas 16-18
Priority area 16
Establish a sustainable national governance structure to coordinate all efforts to minimise antimicrobial resistance.
1 Continue the Primary Industries AMR Coordination Group of both private and public sectors as a forum to exchange information and provide advice and updated information on antimicrobial resistance activities in the animal and agricultural sectors. (This group includes a health representative.)
Year 1 activities
2 Establish a Health AMR Coordination Group to exchange information and provide advice and updated information on human health-related antimicrobial resistance activities, including (but not limited to) equity, stewardship, surveillance, IPC and communications. (This group will include a representative from primary industries.)
3 Establish Ministry of Health and Ministry for Primary Industries leads for Objectives 1 to 4 of the New Zealand AMR Action Plan. These leads will be responsible for working with the Primary Industries and Health AMR coordination groups, and other relevant stakeholders, to plan and co-ordinate implementation, and then for reporting progress for activities under their objective.
4 Establish national governance arrangements to oversee efforts to minimise antimicrobial resistance, co-chaired by the Ministry of Health and the Ministry for Primary Industries. This group will be accountable for the success of the plan and therefore for monitoring progress against the plan’s activities.
Year 2-5 activities
5 Review the effectiveness of the governance arrangements in line with Priority action area 16, activity 4 and revise them as necessary.
6 Review the role and effectiveness of the Health and Primary Industry AMR coordination groups, in line with Priority action area 16, activities 1 and 2, in exchanging information and providing advice and updated information on AMR activities, and revise as necessary.
Priority area 17
Ensure that there is sustainable investment in initiatives to minimise the impacts of antimicrobial resistance. This includes ongoing investment in surveillance, communication, stewardship and infection prevention and control.
1 Explore and use any funding opportunities in the public and private sectors to minimise the impact of antimicrobial resistance, including through communication, surveillance, stewardship and infection prevention and control across human health, animal health and agriculture.
Year 1 activities
2 Develop the business cases required to support implementation of all five objectives of the New Zealand AMR Action Plan, including communication, surveillance, stewardship, infection prevention and control and governance across human health, animal health and agriculture.
Priority area 18
Establish the necessary national and international links and collaborations to implement the AMR Action Plan effectively.
Year 1 activities
1 Identify opportunities for international collaborations and engagement with other governments and international partners on antimicrobial resistance across the human health, animal health and agricultural sectors, and support international governance arrangements.
2 Work with overseas regulatory partners and with international organisations such as WHO, International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH), Organisation for Economic Co‑operation and Development, FAO and OIE to harmonise international data requirements and reporting on antimicrobial resistance.
Years 2–5 activities
3 Based on opportunities identified in Priority action area 18, activities 1 and 2, plan and implement strategic collaborations and engagement with other governments and international partners on antimicrobial resistance across human health, animal health and agricultural sectors.
4 Establish closer ties with other countries to promote the quality, safety and efficacy of antimicrobials; for example, by strengthening veterinary medicine supply chains.